Proxy Report - 16/05/2018
Si les rémunérations 2017 de Mme Gréciet, Directrice Générale, présentent des montants plutôt acceptables, le réel problème de sa rémunération demeure que sa rémunération sous forme d'options et d'actions de performance est assortie de conditions de performance court-termistes.
Non seulement cela ne répond pas aux préconisations de Proxinvest et des investisseurs, mais cela demeure plutôt étonnant de la part d'une biotech. En effet, ces sociétés biopharmaceutiques ont un business-model qui repose lui-même sur le très long-terme ; il semblerait donc tout à fait cohérent que les rémunérations long-terme des dirigeants soient en ligne avec ledit business model.
Onxeo is a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, driven by high therapeutic demand in one of the fastest growing segments of the pharmaceutical industry. Co.'s orphan oncology product portfolio comprises 3 products (Livatag®, Beleodaq®, and AsiDNA™), ranging from preclinical to advanced phases of clinical development.
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
- Proxy reports
- Definition and monitoring of client customized voting guidelines
- Corporate Governance Data and Rating
- Thematic research
- Engagement support
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.